Levetiracetam — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

8 Recruiting

1 Completed trials

12 Sponsors

14 Countries

Phase III

Phase I/II

Phase III: 7 Phase II: 1 Phase I/II: 2 Phase IV: 1 Phase I: 1

Oversight events:

8 temporary halts 1 corrective measure across 3 trials

View oversight register →

Indications tested

Status epilepticus 2 B-cell lymphoma recurrent 1 Ewing's sarcoma 1 Septic shock 1 Cardiac arrest 1 Breast cancer 1 Osteosarcoma 1 B-cell lymphoma refractory 1 Neuroblastoma 1

Sponsors using this IMP

Amgen Inc. 1 Assistance Publique Hopitaux De Paris 1 Fondazione Gimema Franco Mandelli Onlus 1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1 Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau 1 Hospices Civils De Lyon 1 Miltenyi Biomedicine GmbH 1 Neuraxpharm Pharmaceuticals S.L. 1 Odense University Hospital 1 Universitaet Leipzig 1 Universitaet Muenster 1 Universiteit Twente 1

All trials

12 total

DALY II USA/MB-CART2019.1 for DLBCL Pending

2023-508508-39-01 Phase II 2 countries Miltenyi Biomedicine GmbH
Efficacy of prophylactic levetiracetam for improving functional outcome in the acute phase of intracerebral haemorrhage: a randomised, doub… Pending

2024-515663-59-00 Phase III 1 country Hospices Civils De Lyon
Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures Recruiting

2024-514499-42-00 Phase III 9 countries Neuraxpharm Pharmaceuticals S.L.
The LESS-AD trial: A study on the use of levetiracetam to prevent seizures in adults with Down syndrome and Alzheimer's disease. Recruiting

2024-516148-24-00 Phase III 1 country Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
KISS Evaluation of early administration of Levetiracetam in the prevention and treatment of delirium during septic shock: a randomized, doub… Recruiting

2023-510449-51-00 Phase III 1 country Assistance Publique Hopitaux De Paris
Treatment of ELectroencephalographic STatus epilepticus After cardiopulmonary Resuscitation-2 (TELSTAR-2): a multicenter randomised clinical… Recruiting

2024-516068-27-01 Phase III 2 countries Universiteit Twente
Anti-CD19 CAR T-Cell TherApy in Refractory Systemic Autoimmune DISeases - CATARSIS Recruiting

2024-511293-74-01 Phase I/II 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
FAST TRIAL Recruiting

2024-515507-18-00 Phase III 1 country Odense University Hospital
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers Recruiting

2022-501725-21-00 Phase I 1 country Universitaet Muenster
Treatment of Established Status Epilepticus in the Elderly - a prospective, randomized, double-blind comparative effectiveness trial Recruiting

2024-516634-35-00 Phase IV 1 country Universitaet Leipzig
The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended

2023-508968-30-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
A phase 1/2 study of subcutaneous blinatumomab administration in adults and adolescents with R/R and MRD+ B-ALL Halted

2023-506136-32-00 Phase I/II 7 countries Amgen Inc.

Showing 1–12 of 12 trials

← All drugs A–Z